Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras as a Potential Biomarker of Response to Therapy